Welcome to Cannabis Conclusions, a unique educational series from Higher Learning LV that is targeted at hemp and cannabis industry professionals. This series provides readers with the conclusion section from important modern peer-reviewed research studies.
A September 2022 study entitled "Use of Cannabidiol in the Management of Insomnia: A Systematic Review" that was published in the journal Cannabis and Cannabinoid Research critically evaluated "the literature regarding the therapeutic benefits of cannabidiol (CBD) in the management of insomnia."
The study reported that CBD "is often used by patients for the management of insomnia, yet research supporting CBD's effectiveness as a treatment for insomnia is inadequate." The research conducted a search of the following databases "from inception to December 29, 2021: Ovid MEDLINE® and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus."
"CBD is often used by patients for the management of insomnia, yet research supporting CBD's effectiveness as a treatment for insomnia is inadequate."
The project included prior scientific investigations featuring "randomized controlled trials, nonrandomized experimental studies, cross-sectional studies, cohort studies, case series, and case reports." Thirty-four studies were eligible for inclusion in the present analysis.
"All studies reported improvement in the insomnia symptoms of at least a portion of their participants. Of the 34 studies, 19 studies used CBD predominant therapy and 21 studies used nearly equal ratios of CBD to Δ9-tetrahydrocannabinol (THC).
"Of the studies that performed hypothesis testing, four of seven studies with a CBD predominant arm and 12 of 16 studies with a nearly equal ratio of CBD to THC arm reported significant improvement in insomnia outcomes.
"CBD alone or with equal quantities of THC may be beneficial in alleviating the symptoms of insomnia."
"However, only two of the 34 studies focused on patients with insomnia, of which one study was a case report. Additionally, several studies used nonvalidated subjective measures, and most studies failed to include objective measures for symptom assessment.
"The results of our systematic review suggest that CBD alone or with equal quantities of THC may be beneficial in alleviating the symptoms of insomnia. Nevertheless, future research assessing CBDs effectiveness in population of patients specifically with insomnia utilizing validated subjective and objective measures is necessary before definitive inferences can be made."
View the original study.
🎧 Like what you just read? Listen and learn with our highly educational weekly Cannabis Commerce + Chemistry Podcast. At under 30 minutes per episode, it helps industry professionals stay current on trending topics.